Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $37 to $25.
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $37 to $25.